|
|
Novel Ras inhibitor prodrug for colorectal cancer
|
1R43CA206807-01
|
$300,000
|
$300,000
|
CANZONERI, JOSHUA
|
ADT PHARMACEUTICALS, INC.
|
|
|
2/2 The Alabama State University/UAB Comprehensive Cancer Center Partnership
|
3P20CA192976-02S1
|
$20,000
|
$10,600
|
MISHRA, MANOJ
|
ALABAMA STATE UNIVERSITY
|
|
|
2/2 The Alabama State University/UAB Comprehensive Cancer Center Partnership
|
5P20CA192976-03
|
$144,556
|
$76,615
|
MISHRA, MANOJ
|
ALABAMA STATE UNIVERSITY
|
|
|
Age and Diet: Major interacting factors that drive sporadic intestinal cancer
|
5R01CA174432-04
|
$660,173
|
$660,173
|
AUGENLICHT, LEONARD
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
|
DNA Mismatch repair and cancer in murine models
|
5R01CA076329-20
|
$380,585
|
$380,585
|
EDELMANN, WINFRIED
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
|
Small Molecule Activators of Pro-apoptotic BAX for Cancer Therapy
|
5R01CA178394-03
|
$346,525
|
$173,263
|
GAVATHIOTIS, EVRIPIDIS
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
|
Core Support for Cancer Center
|
3P30CA013330-44S1
|
$199,871
|
$23,985
|
GOLDMAN, ISRAEL
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
|
Core Support for Cancer Center
|
3P30CA013330-44S2
|
$199,989
|
$23,999
|
GOLDMAN, ISRAEL
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
|
Core Support for Cancer Center
|
3P30CA013330-44S3
|
$500,000
|
$60,000
|
GOLDMAN, ISRAEL
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
|
Core Support for Cancer Center
|
5P30CA013330-44
|
$3,746,138
|
$449,537
|
GOLDMAN, ISRAEL
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
|
Development of Novel Drugs to Alleviate CPT-11 Toxicity
|
5R01CA161879-06
|
$325,379
|
$325,379
|
MANI, SRIDHAR
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
|
The B7x pathway in the tumor microenvironment
|
5R01CA175495-04
|
$346,525
|
$69,305
|
ZANG, XINGXING
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
|
Colon cancer risk-stratification via optical analysis of rectal ultrastructure
|
1R44CA199667-01A1
|
$1,030,462
|
$1,030,462
|
WALI, RAMESH
|
AMERICAN BIOOPTICS, LLC
|
|
|
Exploiting the immune response to detect pathogen-induced cancers
|
5R01CA199948-02
|
$496,815
|
$496,815
|
LABAER, JOSHUA
|
ARIZONA STATE UNIVERSITY-TEMPE CAMPUS
|
|
|
Couple Communication in Cancer: A Multi-Method Examination
|
1R01CA201179-01A1
|
$693,817
|
$346,909
|
LANGER, SHELBY
|
ARIZONA STATE UNIVERSITY-TEMPE CAMPUS
|
|
|
Navigation from Community to Clinic to promote CRC Screening in Underserved Popul
|
4R01CA162393-05
|
$538,307
|
$538,307
|
LARKEY, LINDA
|
ARIZONA STATE UNIVERSITY-TEMPE CAMPUS
|
|
|
Highly specific ATR inhibitors for the targeted treatment of a broad spectrum of cancers
|
1R41CA203436-01A1
|
$299,998
|
$149,999
|
BROWN, ERIC
|
ATRIN PHARMACEUTICALS
|
|
|
PNNL Proteome Characterization Center
|
1U24CA210955-01
|
$1,123,778
|
$382,085
|
LIU, TAO
|
BATTELLE PACIFIC NORTHWEST LABORATORIES
|
|
|
TRANSCRIPTION FACTORS IN INTESTINAL DIFFERENTIATION AND CANCER
|
1F99CA212433-01
|
$45,076
|
$45,076
|
LO, YUAN-HUNG
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-10S1
|
$118,016
|
$3,540
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-10S2
|
$170,897
|
$5,127
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-10S3
|
$118,875
|
$3,566
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-10S4
|
$499,947
|
$14,998
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-10S5
|
$134,220
|
$4,027
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Baylor College of Medicine Cancer Center
|
5P30CA125123-10
|
$3,253,119
|
$97,594
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Gut L-Histidine Metabolism and Histamine Signaling in Colonic Neoplasia
|
4U01CA170930-04
|
$565,491
|
$565,491
|
VERSALOVIC, JAMES
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
iPGDAC, An Integrative Proteogenomic Data Analysis Center for CPTAC
|
1U24CA210954-01
|
$1,004,827
|
$331,593
|
ZHANG, BING
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
MicroRNA Biomarkers for Determining Treatment Response in Colorectal Cancer
|
1R01CA202797-01A1
|
$360,913
|
$360,913
|
GOEL, AJAY
|
BAYLOR RESEARCH INSTITUTE
|
|
|
Familial and Early Onset Colorectal Cancer
|
5R01CA072851-20
|
$372,400
|
$372,400
|
GOEL, AJAY
|
BAYLOR RESEARCH INSTITUTE
|
|
|
METHYLATION BIOMARKER DEVELOPMENT FOR NONINVASIVE DETECTION OF COLORECTAL CANCER
|
5R01CA181572-03
|
$315,983
|
$315,983
|
GOEL, AJAY
|
BAYLOR RESEARCH INSTITUTE
|
|
|
Development of microRNA Biomarkers For Noninvasive Detection of Colorectal Cancer
|
5R01CA184792-02
|
$359,828
|
$359,828
|
GOEL, AJAY
|
BAYLOR RESEARCH INSTITUTE
|
|
|
Aspirin and Cancer Prevention in Lynch Syndrome: From Cell to Population Data
|
5U01CA187956-03
|
$555,997
|
$555,997
|
GOEL, AJAY
|
BAYLOR RESEARCH INSTITUTE
|
|
|
CpG-ODN Coated Hollow Gold Nanoshells for Photothermal Therapy
|
4R01CA172836-04
|
$342,894
|
$171,447
|
FOSTER, AARON
|
BELLICUM PHARMACEUTICALS, INC.
|
|
|
Modulating systemic pro-oncogenic effects of focal image-guided tumor ablation
|
1R01CA197081-01A1
|
$440,786
|
$145,459
|
AHMED, MUNEEB
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
|
The Tumor Antigens Tn and SialylTn in Human Colorectal Carcinoma
|
5U01CA168930-06
|
$371,065
|
$371,065
|
CUMMINGS, RICHARD
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
|
Modeling KRAS genetic heterogeneity in mouse models
|
1R01CA195744-01A1
|
$535,118
|
$535,118
|
HAIGIS, KEVIN
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
|
Basic and Translational studies of Ras-mutant colorectal cancer
|
5R01CA178017-03
|
$359,556
|
$359,556
|
HAIGIS, KEVIN
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
|
A multi-faceted approach to identifying K-Ras synthetic lethal relationships
|
5U01CA199252-02
|
$1,025,393
|
$512,697
|
HAIGIS, KEVIN
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
|
Defining the Tn-glycoproteome of in situ colorectal tumors and mechanisms of Tn e
|
5F32CA183215-04
|
$64,146
|
$64,146
|
HANES, MELINDA
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
|
Targeting orphan nuclear receptor TR3/Nur77 for tumor angiogenesis
|
5R03CA191463-02
|
$87,000
|
$87,000
|
ZENG, HUIYAN
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
|
Role of c-Cbl in Colon cancer
|
5R01CA175382-03
|
$361,050
|
$361,050
|
CHITALIA, VIPUL
|
BOSTON MEDICAL CENTER
|
|
|
Towards Development of an in vitro Assay to Personalize Colonic Chemoprevention
|
5R03CA195143-02
|
$87,000
|
$87,000
|
ROY, HEMANT
|
BOSTON MEDICAL CENTER
|
|
|
High resolution phase contrast endoscopy
|
5R01CA182939-03
|
$345,234
|
$345,234
|
MERTZ, JEROME
|
BOSTON UNIVERSITY (CHARLES RIVER CAMPUS)
|
|
|
Variations in Needs after Colorectal Cancer Diagnosis
|
5R01CA181392-03
|
$607,762
|
$607,762
|
BOEHMER, ULRIKE
|
BOSTON UNIVERSITY MEDICAL CAMPUS
|
|
|
IGPR-1 in colon cancer chemotherapy
|
5R21CA193958-02
|
$178,024
|
$178,024
|
RAHIMI, NADER
|
BOSTON UNIVERSITY MEDICAL CAMPUS
|
|
|
A Follow-up Study for Causes of Cancer in Black Women
|
4UM1CA164974-05
|
$3,236,402
|
$647,280
|
ROSENBERG, LYNN
|
BOSTON UNIVERSITY MEDICAL CAMPUS
|
|
|
Alliance for Clinical Trials in Oncology Operations Center
|
3U10CA180821-03S1
|
$1,595,651
|
$79,783
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
|
Alliance for Clinical Trials in Oncology Operations Center
|
3U10CA180821-03S2
|
$550,000
|
$27,500
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
|
Alliance for Clinical Trials in Oncology Operations Center
|
3U10CA180821-03S3
|
$750,000
|
$37,500
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
|
Alliance for Clinical Trials in Oncology Operations Center
|
5U10CA180821-03
|
$9,068,022
|
$453,401
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Total relevant funding to Colon/Rectum for this search: $212,173,293
|
